Gujarat Themis Biosyn Approves QIP Closure Raised at ₹354 Share

MUMBAI — Active pharmaceutical ingredient (API) manufacturer Gujarat Themis Biosyn Limited formally approved the closure of its Qualified Institutions Placement (QIP) on Friday, August 28, 2026, successfully raising ₹750 crore (approx. USD 90 million).

The decision was finalized during a meeting of the company's Fund-Raising Committee held between 8:15 p.m. and 8:30 p.m. IST, following the receipt of completed application forms and institutional funds in the designated escrow account. The board approved the allotment of 2,11,86,440 fully paid-up equity shares to eligible Qualified Institutional Buyers (QIBs) at an issue price of ₹354 per share. The fresh equity issuance represents a strategic effort by the Vapi-based biopharmaceuticals producer to strengthen its operational balance sheet and fund planned capacity expansions.

Issue Execution, Pricing Breakdown, and Regulatory Compliance

The QIP was officially opened on August 25, 2026, following preliminary institutional disclosures and corporate board authorisations.

According to statutory disclosures filed under Chapter VI of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (SEBI ICDR Regulations), the equity shares possess a face value of ₹1 each. The finalized issue price of ₹354 per share incorporates an equity premium component of ₹353 per share.

The Fund-Raising Committee applied a discount of ₹18.57 per equity share (4.98 percent) on the calculated floor price of ₹372.57 per share. The price adjustment remains fully compliant with the regulatory threshold permitted under Regulation 176(1) of the SEBI ICDR Regulations.

Along with declaring the formal closure of the issue period, the committee approved and adopted the final placement document dated August 28, 2026, and authorized the immediate dispatch of Confirmation of Allocation Notes (CAN) to participating QIBs.

Balance Sheet Strengthening and Corporate Impact

The completion of the ₹750 crore institutional capital raise significantly increases Gujarat Themis Biosyn’s net worth and provides non-debt financing for its ongoing capital expenditure projects.

• Issuing Entity: Gujarat Themis Biosyn Limited (NSE Symbol: GUJTHEM, BSE Scrip Code: 506879).

• Total Equity Allocated: 2,11,86,440 fully paid-up equity shares of face value ₹1 each.

• Pricing Parameters: Issue price fixed at ₹354 per share (including a 4.98% discount on the ₹372.57 floor price).

• Regulatory Compliance: Executed pursuant to SEBI ICDR Regulations and SEBI LODR Regulations, 2015.

For retail equity investors, the institutional participation reflects market interest in the company's fermentation-based API manufacturing facilities. The capital raised will support specialized research and development, facility upgrades at its primary manufacturing location in Vapi, Gujarat, and global regulatory compliance steps for international market expansion.

Official Sources

According to official regulatory filings submitted to the National Stock Exchange of India Limited (NSE) and BSE Limited on August 28, 2026, by Company Secretary and Compliance Officer Vineet Gawankar on behalf of Gujarat Themis Biosyn Limited, the QIP issue period was closed after fulfilling all escrow requirements. Complete placement documentation has been made available on the official corporate portal of Gujarat Themis Biosyn Limited.

Quote Section

"According to officials from Gujarat Themis Biosyn Limited, the Fund-Raising Committee approved and declared the closure of the QIP issue period on August 28, 2026, pursuant to the receipt of application forms and funds in the escrow account from eligible qualified institutional buyers."

Why It Matters

The successful execution of the QIP provides long-term capital to Gujarat Themis Biosyn without creating debt obligations or short-term liquidity pressures. By expanding its equity base at ₹354 per share, the company is positioned to accelerate its biopharmaceutical manufacturing operations, enhance API production capacities, and serve expanding domestic and export healthcare supply chains.

Key Facts at a Glance

• Issue Closure: Gujarat Themis Biosyn officially closed its Qualified Institutions Placement on August 28, 2026.

• Capital Raised: Allocated 2,11,86,440 equity shares, raising approximately ₹750 crore.

• Issue Pricing: Fixed at ₹354 per share (Face Value ₹1 + Premium ₹353), reflecting a 4.98% discount to the floor price.

• Issue Duration: Opened on August 25, 2026, and closed on August 28, 2026.

• Filing Authorities: Formally disclosed to BSE and NSE under Regulation 30 of SEBI LODR Regulations.

Frequently Asked Questions

What was the final issue price for the Gujarat Themis Biosyn QIP?

The final issue price was determined at ₹354 per equity share, which includes a face value of ₹1 and an equity premium of ₹353 per share.

How many shares were allotted in the QIP?

The Fund-Raising Committee approved the allotment of 2,11,86,440 equity shares to participating Qualified Institutional Buyers.

Did the company offer a discount on the QIP floor price?

Yes. Gujarat Themis Biosyn applied a discount of ₹18.57 per share (4.98 percent) on the SEBI-calculated floor price of ₹372.57 per share.

When did the QIP open and close?

The QIP opened on August 25, 2026, and formally closed on August 28, 2026, following the receipt of funds in the escrow account.

Source: Official regulatory filing submitted to BSE Limited and National Stock Exchange of India Limited by Gujarat Themis Biosyn Limited on August 28, 2026.